

# Summary of Product Characteristics

## 1 NAME OF THE MEDICINAL PRODUCT

Reminyl XL 8 mg prolonged-release capsules, hard

## 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 8 mg capsule contains galantamine (ashydrobromide)

Excipient with known effect: sucrose

For the full list of excipients, see section 6.1

## 3 PHARMACEUTICAL FORM

Prolonged release capsule, hard

*Product imported from Italy and Greece*

White opaque, size 4 hard capsules with the inscription "G8" containing white to off-white pellets

## 4 CLINICAL PARTICULARS

As per PA23211/003/002

## 5 PHARMACOLOGICAL PROPERTIES

As per PA23211/003/002

## 6 PHARMACEUTICAL PARTICULARS

### 6.1 List of excipients

*Prolonged release pellets*

Diethyl phthalate

Ethylcellulose

Hypromellose

Macrogol 400

Maize starch

Sucrose

*Capsules*

Gelatin

Titanium dioxide (E171)

*Imprinting ink*

Iron oxide Black (E172)

Shellac

Propylene glycol (E1520)

### 6.2 Incompatibilities

Not applicable.

### 6.3 Shelf life

The shelf life expiry date of this product shall be the date shown on the container and outer package of the product on the market in the country of origin.

#### **6.4 Special precautions for storage**

Do not store above 30°C.

#### **6.5 Nature and contents of container**

Carton containing 4 blister strips (7 capsules per strip).

Pack size: 28 capsules

#### **6.6 Special precautions for disposal of a used medicinal product or waste materials derived from such medicinal product and other handling of the product**

No special requirements.

### **7 PARALLEL PRODUCT AUTHORISATION HOLDER**

PCO Manufacturing Ltd.  
Unit 10, Ashbourne Business Park  
Rath  
Ashbourne  
Co. Meath  
Ireland

### **8 PARALLEL PRODUCT AUTHORISATION NUMBER**

PPA0465/166/002

### **9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 25<sup>th</sup> September 2009

### **10 DATE OF REVISION OF THE TEXT**

April 2022